Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Cogent Biosciences (COGT) Accumulated Depreciation & Amortization (2017 - 2025)

Cogent Biosciences' Accumulated Depreciation & Amortization history spans 9 years, with the latest figure at $8.7 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 41.93% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 41.93% year-over-year, with the annual reading at $8.7 million for FY2025, 41.93% up from the prior year.
  • Accumulated Depreciation & Amortization came in at $8.7 million for Q4 2025, up from $6.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.7 million in Q4 2025 to a low of $559000.0 in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $3.7 million (2023), against an average of $4.1 million.
  • Year-over-year, Accumulated Depreciation & Amortization surged 35.68% in 2021 and then soared 161.6% in 2023.
  • Cogent Biosciences' Accumulated Depreciation & Amortization stood at $559000.0 in 2021, then soared by 150.63% to $1.4 million in 2022, then skyrocketed by 161.6% to $3.7 million in 2023, then soared by 66.85% to $6.1 million in 2024, then soared by 41.93% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for COGT's Accumulated Depreciation & Amortization are $8.7 million (Q4 2025), $6.1 million (Q4 2024), and $3.7 million (Q4 2023).